Their activating antibodies have the potential to produce superior clinical results compared to first-generation immune checkpoint inhibitors by simultaneously modulating innate and adaptive immunity. They are also exploring the use of antagonist antibodies for treating autoimmune diseases. ImCheck benefits from the support of leading researchers, an experienced management team, and prominent investors from the US and Europe.